Inovio Pharmaceuticals (STU:GBM) Operating Margin %: 0.00% (As of Mar. 2026)


STU:GBM Inovio Pharmaceuticals Inc STU:GBM
43 GF Score
Price €0.95
GF Value €0.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Operating Margin %?

Inovio Pharmaceuticals STU:GBM -0.83% 43 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:GBM with a GF Score™ of 43/100 and a GF Value™ of €0.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, Inovio Pharmaceuticals ranks worse than 106269.82% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Inovio Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was €-18.99 Mil. Inovio Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Inovio Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Warning Sign:

Inovio Pharmaceuticals Inc operating margin has been in a 5-year decline. The average rate of decline per year is -116.6%.

The historical rank and industry rank for Inovio Pharmaceuticals's Operating Margin % or its related term are showing as below:


STU:GBM's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

Inovio Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was -116.60% per year.

Inovio Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was €-18.99 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-72.00 Mil.


Inovio Pharmaceuticals  (STU:GBM) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Inovio Pharmaceuticals Operating Margin % Related Terms


Inovio Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Operating Margin % Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16,968.68 -2,607.52 -16,035.78 -51,606.25 -132,403.57

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38,620.00 0.00 0.00 0.00 0.00

STU:GBM vs NRXS, FBIO, PYPD: Operating Margin % Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Operating Margin % falls into.


STU:GBM
43GF Score
Inovio Pharmaceuticals Inc STU:GBM
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Inovio Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-74.146 / 0.056
=-132,403.57 %

Inovio Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-18.987 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Inovio Pharmaceuticals (STU:GBM) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Inovio Pharmaceuticals and its competitors. According to the industry distribution chart, Inovio Pharmaceuticals ranks #999999 out of 941 companies in the Biotechnology industry.
Is Inovio Pharmaceuticals' Operating Margin % too high?
Inovio Pharmaceuticals' current Operating Margin % is 0.00%. Based on the distribution chart, Inovio Pharmaceuticals ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inovio Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Operating Margin % compare to NRXS and FBIO?
According to the Biotechnology industry distribution chart, Inovio Pharmaceuticals ranks #999999 out of 941 companies for Operating Margin %. This places Inovio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (STU:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.95 — trading 401.8% above its estimated fair value. The current Operating Margin % is 0.00%. Inovio Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Inovio Pharmaceuticals (STU:GBM), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (STU:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €0.95 is trading 401.8% above its estimated GF Value™ of €0.19. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:GBM:

  • Operating Margin %: 0.00%
  • GF Value™: €0.19 vs. price of €0.95 (401.8% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USAINO:Mexico0A43:UK
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
43GF Score

Get the complete analysis for STU:GBM

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€0.19
GF Value